SNY Stock Analysis & IQ Rating | Sanofi

Chart

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY). Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25 setting a €110 price target. The same day Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of moderate-to-severe chronic [….]

Today

Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation. Sanofi stock dropped Wednesday after French authorities raided the drugmakers Paris headquarters as part of a tax fraud investigation.The post Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation appeared first on Investor'.s Business Daily.

Wed Nov 26, 2025

Milestones Over Sales: The Sanofi Partnership Now Drives Novavaxs Outlook.

Wed Nov 26, 2025

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe. ) an unannounced visit on Tuesday as tax investigators accompanied by prosecutors and specialist aides searched the site amid a widening financial probe.French prosecutors confirmed that Sanofi is the focus of a preliminary investigation launched in January 2024 into alleged money laundering of tax fraud including potential involvement by an organized group and possible criminal conspiracy Le Monde .The company said it used

Tue Nov 25, 2025

Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale.

Tue Nov 25, 2025

Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria. Sanofi and Regeneron'.s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria The unpredictable nature of chronic spontaneous urticaria leaves patients guessing when they'.ll have their next outbreak of disruptive debilitating hives and itch which can make life challenging said Dupixent

Tue Nov 25, 2025

Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug. Texas Attorney General ) and ) of concealing critical information about the effectiveness of their Plavix.According to the the companies marketed Plavix—also sold generically as clopidogrel bisulfate—as a reliable treatment to prevent heart attacks strokes and blood clots.State officials argue the drugmakers failed to disclose that the medication works poorly or not at all for a

Fri Nov 21, 2025

SNY Makes Notable Cross Below Critical Moving Average. In trading on Tuesday shares of Sanofi (Symbol: SNY) crossed below their 200 day moving average of $50.97 changing hands as low as $50.48 per share. Sanofi shares are currently trading off about 2.4% on the day. The chart below shows the one year performance of SNY shares v

Tue Nov 18, 2025

CING: Third Quarter Results. By Cingulate Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13th 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the FDA was accepted and a PDUFA date of May 31st 2026 was given. Cingulate also saw changes in its management ranks as the companys focus shifts to pre-commercialization activities which included the appointment of Bryan Downey as Chief Commercial Officer. Company representa

Mon Nov 17, 2025

LGND: Target Up On Improved Growth Outlook. By Ligand Pharmaceuticals Inc. (NASDAQ:LGND) reported outstanding results for its third quarter with revenues almost double our estimates and adjusted core earnings per share (EPS) more than 60% greater. While contributions from the spin out of Pelthos contributed the most revenue growth in other areas was also strong. Royalties grew almost 50% and Captisol increased over 70%. Other activity since the previous quarterly update includes a $460 million c

Mon Nov 10, 2025